Chardan Maintains A Buy Recommendation On CRISPR Therapeutics AG (CRSP)

TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while ...
Zacks Investment Research on MSN

CRISPR Therapeutics AG (CRSP) sees a more significant dip than broader market: Some facts to know

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $53.19, marking a -1.45% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.14%. At ...
Zacks Investment Research on MSN

Here is what to know beyond why CRISPR Therapeutics AG (CRSP) is a trending stock

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Contrarius Global Equity Fund’s Thoughts on CRISPR Therapeutics’ (CRSP) Gene Editing Therapy

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...

CRISPR Therapeutics Reports Strong 90% Response Rate and Lupus Remission in Landmark Zugo-Cel Update

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR Therapeutics released a comprehensive clinical update on zugocaptagene geleucel ...

Cathie Wood’s ARK boosts CRISPR stock with significant buy

Earlier in the week, ARK purchased 10,353 shares of CRISPR on Wednesday, valued at $584,530, and 43,333 shares on Tuesday, totaling $2,509,414. This consistent buying pattern suggests a strong ...

These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026?

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Agios Pharma (AGIO)

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.